Fruquintinib (HMPL-013)

For research use only. Not for use in humans.

目录号:S5667

Fruquintinib (HMPL-013) Chemical Structure

CAS No. 1194506-26-7

Fruquintinib (HMPL-013) is a small molecule inhibitor with strong potency and high selectivity against VEGFR family. It inhibits VEGFR 1, 2, 3, with IC50 values of 33 nM, 35 nM and 0.5 nM, respectively and shows only weak inhibition of RET, FGFR-1 and c-kit kinases.

规格 价格 库存 购买数量  
RMB 1040.82 现货
RMB 3194.89 现货
RMB 7289.27 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Fruquintinib (HMPL-013)发表文献1篇:

产品安全说明书

VEGFR抑制剂选择性比较

生物活性

产品描述 Fruquintinib (HMPL-013) is a small molecule inhibitor with strong potency and high selectivity against VEGFR family. It inhibits VEGFR 1, 2, 3, with IC50 values of 33 nM, 35 nM and 0.5 nM, respectively and shows only weak inhibition of RET, FGFR-1 and c-kit kinases.
靶点
VEGFR3 [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
0.5 nM 33 nM 35 nM
体外研究

In in vitro enzymatic and cellular assays, Fruquintinib inhibits VEGFR family kinases and suppressed VEGF/VEGFR cell signaling in human umbilical vein endothelial cell (HUVEC) and human lymphatic endothial cell (HLEC) with IC50 at low nanomolar level. Few kinases are inhibited other than VEGFRs in a panel of 253 kinases test. Fruquintinib is a highly potent inhibitor of VEGF-induced angiogenesis[1].

体内研究 Fruquintinib demonstrates favorable pharmacokinetic profile in multiple animal species, oral administration of fruquintinib strongly suppressed VEGF-induced VEGFR2 phosphorylation in the lung tissue in mice. The extent and duration of the inhibition of VEGFR2 phosphorylation correlated well with drug exposures. The strong anti-angiogenic effect resulted in robust anti-tumor efficacy in a number of human tumor xenograft models with good dose response[1].

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

- 合并
  • Cell lines: Primary HUVEC cells
  • Concentrations: 0.005, 0.05, 0.5 μM
  • Incubation Time: 18 hours
  • Method:

    Primary HUVEC cells at 2 × 104 cells/well were seeded in flat bottomed 96-well plates with 100 mL media containing 0.5% FBS. The next day, cells were treated with fruquintinib for 18 hours at 37 C. The cell survival was determined by AlamarBlue assay. The plates were incubated for 3 hours at 37 C and fluorescence value was read at Ex 530 nm and Em 590 nm on Tecan.


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: Female Balb/c nude mice at the age of 10-11 weeks
  • Dosages: 2.5 mg/kg
  • Administration: oral
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 6 mg/mL (15.25 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 393.39
化学式

C21H19N3O5

CAS号 1194506-26-7
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04716634 Recruiting Drug: Tislelizumab|Drug: Fruquintinib Advanced Solid Tumors BeiGene|Hutchison Medipharma Limited April 19 2021 Phase 2
NCT04557397 Completed Drug: Fruquintinib|Drug: Itraconazole|Drug: Rifampin Drug Drug Interaction Hutchison Medipharma Limited|Covance September 2 2020 Phase 1
NCT02689752 Completed Drug: fruquintinib Healthy Hutchison Medipharma Limited July 2016 Phase 1
NCT02415023 Completed Drug: fruquintinib+paclitaxel Gastric Cancer Hutchison Medipharma Limited November 9 2014 Phase 1|Phase 2
NCT01955304 Completed Drug: fruquintinib Food Effect of Fruquintinib in Health Subjects Hutchison Medipharma Limited June 2012 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

VEGFR Signaling Pathway Map

相关VEGFR产品

Tags: 购买Fruquintinib (HMPL-013) | Fruquintinib (HMPL-013)供应商 | 采购Fruquintinib (HMPL-013) | Fruquintinib (HMPL-013)价格 | Fruquintinib (HMPL-013)生产 | 订购Fruquintinib (HMPL-013) | Fruquintinib (HMPL-013)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID